INTERVENTIONS FOR VALVULAR DISEASE AND HEART FAILURE

Transcatheter aortic valve implantation with the 34 mm self-expanding CoreValve Evolut R: initial experience in 101 patients from a multicentre registry

EuroIntervention 2018;14:e301-e305 published online May 2018 published online e-edition June 2018. DOI: 10.4244/EIJ-D-17-01153

Christian Kuhn
Christian Kuhn1,2, MD; Christian Frerker3, MD; Anne-Kathrin Meyer1, BS; Thomas Kurz4, MD; Ulrich Schäfer5, MD; Florian Deuschl5, MD; Mohamed Abdel-Wahab6, MD; Dimitry Schewel3, MD; Ahmed Elghalban6, MD; Karl-Heinz Kuck3, MD; Norbert Frey1,2, MD; Derk Frank1,2*, MD
1. Department of Internal Medicine III (Cardiology, Angiology, Intensive Care), UKSH, Kiel, Germany; 2. DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Kiel, Germany; 3. Department of Cardiology, Asklepios St. Georg, Ha

Aims: The recently released Medtronic CoreValve Evolut R 34 mm is the largest self-expanding transcatheter heart valve ever developed. Clinical data for this device size are scarce. We th

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

aortic stenosisdegenerative valvetavi
Interventions for valvular diseaseTAVI
Read next article
Prognostic impact of non-culprit chronic total occlusions in infarct-related cardiogenic shock: results of the randomised IABP-SHOCK II trial

Latest news